Levonorgestrel-releasing intrauterine system versus oral progestogens for non-atypical endometrial hyperplasia: predictors for treatment failure

Authors

  • Yuen Jim James Law Department of Obstetrics & Gynecology, Tuen Mun Hospital, Hong Kong SAR, China
  • Lee Ting Kwong
  • Po Lam So

DOI:

https://doi.org/10.12809/hkjgom.23.2.339

Keywords:

Endometrial hyperplasia, Levonorgestrel, Medroxyprogesterone, Metrorrhagia, Norethisterone, Recurrence

Abstract

Objective: This study aims to compare treatment outcomes of a levonorgestrel-releasing intrauterine system (LNGIUS) or oral progestogens in women with non-atypical endometrial hyperplasia (EH). Additionally, the predictors for EH non-regression were determined.
Methods: Medical records of women diagnosed with non-atypical EH between April 2016 and March 2022 at Tuen Mun Hospital were retrieved. These patients were offered LNG-IUS as the first-line option or oral progestogens if they refused or had LNG-IUS contraindications such as submucosal fibroid distorting endometrial cavity. The rate of EH non-regression at 12 months and the rate of EH relapse at 24 and 36 months between groups were compared. Univariate and multivariate analyses were conducted to identify predictors for EH non-regression.
Results: The median follow-up duration was 24 months for the LNG-IUS group and 19 months for the oral progestogens group. The rate of EH regression at 12 months was higher in the LNG-IUS group (93.9% vs 71.2%, p<0.001). The rate of EH relapse was higher in the oral progestogens group at 24 months (21.1% vs 1.1%, p=0.003) and 36 months (33.3% vs 2.3%, p=0.014). The incidence of hysterectomy for treatment failure was higher in the oral progestogens group (13.7% vs 4.2%, p=0.005). No EH relapse occurred in either group after 36 months post-treatment. Predictors for EH non-regression were postmenopausal status (odds ratio=5.80, p=0.022) and oral progestogens treatment (odds ratio=7.51, p<0.001).
Conclusion: In women with non-atypical EH, treatment with LNG-IUS leads to a higher regression rate at 12 months, a lower relapse rate within 36 months, and a lower rate of hysterectomy due to treatment failure, compared with treatment with oral progestogens. Postmenopausal status and treatment with oral progestogens are risk factors for treatment failure. Regular endometrial surveillance should be provided to women at risk. Hysterectomy is recommended for postmenopausal women.

References

Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 women. Cancer 1985;56:403-12. DOI: https://doi.org/10.1002/1097-0142(19850715)56:2<403::AID-CNCR2820560233>3.0.CO;2-X

Reed SD, Newton KM, Clinton WL, et al. Incidence of endometrial hyperplasia. Am J Obstet Gynecol 2009;200:678.e1-6. DOI: https://doi.org/10.1016/j.ajog.2009.02.032

Anastasiadis PG, Skaphida PG, Koutlaki NG, Galazios GC, Tsikouras PN, Liberis VA. Descriptive epidemiology of endometrial hyperplasia in patients with abnormal uterine bleeding. Eur J Gynaecol Oncol 2000;21:131-4.

Lacey JV Jr, Sherman ME, Rush BB, et al. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol 2010;28:788-92. DOI: https://doi.org/10.1200/JCO.2009.24.1315

Terakawa N, Kigawa J, Taketani Y, et al. The behavior of endometrial hyperplasia: a prospective study. Endometrial Hyperplasia Study Group. J Obstet Gynaecol Res 1997;23:223-30. DOI: https://doi.org/10.1111/j.1447-0756.1997.tb00836.x

Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and meta-analysis. Am J Obstet Gynecol 2010;203:547.e1-10. DOI: https://doi.org/10.1016/j.ajog.2010.07.037

Gallos ID, Krishan P, Shehmar M, Ganesan R, Gupta JK. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study. Hum Reprod 2013;28:2966-71. DOI: https://doi.org/10.1093/humrep/det320

Management of Endometrial Hyperplasia (Green-top Guideline No. 67). Royal College of Obstetricians and Gynaecologists (RCOG) and the British Society for Gynaecological Endoscopy (BSGE) Joint Guideline, February 2016.

Committee on Gynecologic Practice Society of Gynecologic Oncology. Committee Opinion No. 631 – Endometrial Intraepithelial Neoplasia. Obstet Gynecol 2015;125:1272-78. DOI: https://doi.org/10.1097/01.AOG.0000465189.50026.20

Ring KL, Mills AM, Modesitt SC. Endometrial hyperplasia. Obstet Gynecol 2022;140:1061-75.

Auclair MH, Yong PJ, Salvador S, Thurston J, Colgan TTJ, Sebastianelli A. Guideline No. 390 -Classification and Management of Endometrial Hyperplasia. J Obstet Gynaecol Can 2019;41:1789-800.

The Hong Kong College of Obstetricians and Gynaecologists. Guidelines on Clinical Management of Endometrial Hyperplasia. Available at: https://www.hkcog.org.hk/hkcog/Download/Guidelines_on_Clinical_Management_of_Endometrial_Hyperplasia.pdf.

Ørbo A, Arnes M, Hancke C, Vereide AB, Pettersen I, Larsen K. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. Gynecol Oncol 2008;111:68-73. DOI: https://doi.org/10.1016/j.ygyno.2008.06.014

Varma R, Soneja H, Bhatia K, et al. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia—a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol 2008;139:169-75. DOI: https://doi.org/10.1016/j.ejogrb.2008.02.022

Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol (Oxf) 1982;17:529-36. DOI: https://doi.org/10.1111/j.1365-2265.1982.tb01625.x

FSRH Clinical Guideline: Intrauterine Contraception. Available at: https://www.fsrh.org/documents/ceuguidanceintrauterinecontraception/.

National Institute for Clinical Excellence. Long-acting reversible contraception: the effective and appropriate use of long-acting reversible contraception. Available at: https://www.nice.org.uk/guidance/cg30/documents/longacting-reversible-contraception-clinical-guideline-first-consultation-nice-guideline2.

Mansour D, Gemzell-Danielsson K, Inki P, Jensen JT. Fertility after discontinuation of contraception: a comprehensive review of the literature. Contraception 2011;84:465-77. DOI: https://doi.org/10.1016/j.contraception.2011.04.002

Ørbo A, Arnes M, Vereide AB, Straume B. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens. BJOG 2016;123:1512-9. DOI: https://doi.org/10.1111/1471-0528.13763

Yin J, Ma S, Shan Y, et al. Risk factors for recurrence in patients with atypical endometrial hyperplasia and endometrioid adenocarcinoma after fertility-sparing treatments. Cancer Prev Res (Phila) 2020;13:403-10.

Pal N, Broaddus RR, Urbauer DL, et al. Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine device. Obstet Gynecol 2018;131:109-16. DOI: https://doi.org/10.1097/AOG.0000000000002390

Zhou S, Xu Z, Yang B, et al. Characteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia women receiving second-line fertility-sparing treatment. J Gynecol Oncol 2021;32:e57.

Yang X, Wang J. The role of metabolic syndrome in endometrial cancer: a review. Front Oncol 2019;9:744.

Rotenberg O, Fridman D, Doulaveris G, et al. Long-term outcome of postmenopausal women with non-atypical endometrial hyperplasia on endometrial sampling. Ultrasound Obstet Gynecol 2020;55:546-51.

Hedrick Ellenson L, Ronnett BM, Kurman RJ. Precursor Lesions of Endometrial Carcinoma. In: Kurman RJ, Hedrick Ellenson L, Ronnett BM, editors. Blaustein’s Pathology of the Female Genital Tract, 6th ed. New York: Springer; 2010;360-1. DOI: https://doi.org/10.1007/978-1-4419-0489-8_8

Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ. Uterine Corpus. In: Histological Typing of Female Genital Tract Tumours, 2nd ed. New York: Springer-Verlag; 1994:13. DOI: https://doi.org/10.1007/978-3-642-85014-1_2

Silverberg SG, Mutter GL, Kurman RJ, Kubik-Huch RA, Nogales F, Tavassoli FA. Tumors of the Uterine Corpus: Epithelial Tumors and Related Lesions. In: Tavassoli FA, Stratton MR, editors. WHO Classification of Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs Lyon: IARC Press; 2003:221-32.

Emons G, Beckmann MW, Schmidt D, Mallmann P; Uterus commission of the Gynecological Oncology Working Group (AGO). New WHO Classification of Endometrial Hyperplasias. Geburtshilfe Frauenheilkd 2015;75:135-6. DOI: https://doi.org/10.1055/s-0034-1396256

Downloads

Published

2023-06-02

How to Cite

1.
Law YJJ, Kwong LT, So PL. Levonorgestrel-releasing intrauterine system versus oral progestogens for non-atypical endometrial hyperplasia: predictors for treatment failure. Hong Kong J Gynaecol Obstet Midwifery [Internet]. 2023 Jun. 2 [cited 2024 Apr. 21];23(2). Available from: https://hkjgom.org/home/article/view/339

Issue

Section

Original Article

Most read articles by the same author(s)